TY - JOUR T1 - Sarcoidosis complicating treatment with natalizumab for Crohn's disease JF - Thorax JO - Thorax SP - 1109 LP - 1110 DO - 10.1136/thx.2010.155762 VL - 66 IS - 12 AU - C A Parisinos AU - C W Lees AU - W A H Wallace AU - J Satsangi Y1 - 2011/12/01 UR - http://thorax.bmj.com/content/66/12/1109.abstract N2 - Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients. ER -